What is the share price of Welcure Drugs and Pharmaceuticals Ltd (WELCURE) today?
The share price of WELCURE as on 25th June 2025 is ₹14.35. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Welcure Drugs and Pharmaceuticals Ltd (WELCURE) share?
The past returns of Welcure Drugs and Pharmaceuticals Ltd (WELCURE) share are- Past 1 week: 27.12%
- Past 1 month: 34.78%
- Past 3 months: 53.61%
- Past 6 months: 5.52%
- Past 1 year: 203.21%
- Past 3 years: 88.04%
- Past 5 years: 2296.83%
What are the peers or stocks similar to Welcure Drugs and Pharmaceuticals Ltd (WELCURE)?
The peers or stocks similar to Welcure Drugs and Pharmaceuticals Ltd (WELCURE) include:What is the market cap of Welcure Drugs and Pharmaceuticals Ltd (WELCURE) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Welcure Drugs and Pharmaceuticals Ltd (WELCURE) is ₹178.78 Cr as of 25th June 2025.What is the 52 week high and low of Welcure Drugs and Pharmaceuticals Ltd (WELCURE) share?
The 52-week high of Welcure Drugs and Pharmaceuticals Ltd (WELCURE) is ₹15.89 and the 52-week low is ₹4.90.What is the PE and PB ratio of Welcure Drugs and Pharmaceuticals Ltd (WELCURE) stock?
The P/E (price-to-earnings) ratio of Welcure Drugs and Pharmaceuticals Ltd (WELCURE) is 82.39. The P/B (price-to-book) ratio is 133.42.Which sector does Welcure Drugs and Pharmaceuticals Ltd (WELCURE) belong to?
Welcure Drugs and Pharmaceuticals Ltd (WELCURE) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Welcure Drugs and Pharmaceuticals Ltd (WELCURE) shares?
You can directly buy Welcure Drugs and Pharmaceuticals Ltd (WELCURE) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Welcure Drugs and Pharmaceuticals Ltd
WELCURE Share Price
14.354.97% (-0.75)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
WELCURE Stock Scorecard
Performance
HighThe creamy layer - amongst the top performing stocks
Valuation
HighSeems to be overvalued vs the market average
Growth
HighStrong financials and growth story over the years
Profitability
LowProfitability and efficiency haven't been upto the mark
Entry point
BadThe stock is in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
WELCURE Performance & Key Metrics
WELCURE Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 44.03 | 133.42 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 35.49 | 6.52 | 0.85% |
WELCURE Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
WELCURE Company Profile
Welcure Drugs & Pharmaceuticals Ltd. is engaged in wholesaling of pharmaceutical and medical goods.
SUNPHARMA
PE Ratio
36.50
36.50
1Y Return
11.19%
11.19%
Buy Reco %
87.88
87.88
CIPLA
PE Ratio
22.97
22.97
1Y Return
0.13%
0.13%
Buy Reco %
74.19
74.19
DRREDDY
PE Ratio
19.39
19.39
1Y Return
10.43%
10.43%
Buy Reco %
56.67
56.67
TORNTPHARM
PE Ratio
56.06
56.06
1Y Return
11.99%
11.99%
Buy Reco %
72.00
72.00
ZYDUSLIFE
PE Ratio
21.17
21.17
1Y Return
10.72%
10.72%
Buy Reco %
46.43
46.43
WELCURE Forecast
WELCURE Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
WELCURE
WELCURE
Income
Balance Sheet
Cash Flow
Annual Normal View
WELCURE Income Statement
WELCURE Income Statement
Annual Normal View
| Financial Year | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0.09 | 0.05 | 0.08 | 0.08 | 0.13 | 0.11 | 0.24 | 0.09 | 26.46 | 48.55 | ||||||||||
Raw Materials | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 23.67 | 44.42 | ||||||||||
| Power & Fuel Cost | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||||
| Employee Cost | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.08 | ||||||||||||
| Selling & Administrative Expenses | 0.06 | 0.07 | 0.07 | 0.09 | 0.08 | 0.08 | 0.10 | 0.13 | ||||||||||||
| Operating & Other expenses | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | ||||||||||||
EBITDA | 0.03 | -0.02 | 0.00 | -0.01 | 0.05 | 0.03 | 0.11 | -0.14 | 2.79 | 4.13 | ||||||||||
| Depreciation/Amortization | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 0.01 | 0.02 | ||||||||||
| PBIT | 0.03 | -0.02 | 0.00 | -0.01 | 0.05 | 0.03 | 0.11 | -0.18 | 2.78 | 4.11 | ||||||||||
| Interest & Other Items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | ||||||||||
| PBT | 0.03 | -0.02 | 0.00 | -0.01 | 0.05 | 0.03 | 0.11 | -0.18 | 2.78 | 4.11 | ||||||||||
| Taxes & Other Items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.61 | 0.05 | ||||||||||
| Net Income | 0.03 | -0.02 | 0.00 | -0.01 | 0.05 | 0.03 | 0.11 | -0.18 | 2.17 | 4.06 | ||||||||||
| EPS | 0.02 | -0.02 | 0.00 | -0.01 | 0.04 | 0.02 | 0.08 | -0.13 | 0.36 | 3.00 | ||||||||||
| DPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
| Payout ratio | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
WELCURE Company Updates
WELCURE Stock Peers
WELCURE Past Performance & Peer Comparison
WELCURE Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation-basic on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation-basic on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Welcure Drugs and Pharmaceuticals Ltd | 82.39 | 133.42 | — |
| Sun Pharmaceutical Industries Ltd | 36.50 | 5.94 | 0.96% |
| Cipla Ltd | 22.97 | 4.52 | 1.07% |
| Dr Reddy's Laboratories Ltd | 19.39 | 3.88 | 0.61% |
WELCURE Stock Price Comparison
Compare WELCURE with any stock or ETFCompare WELCURE with any stock or ETF
WELCURE
WELCURE Holdings
WELCURE Shareholdings
WELCURE Promoter Holdings Trend
WELCURE Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
WELCURE Institutional Holdings Trend
WELCURE Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
WELCURE Shareholding Pattern
WELCURE Shareholding Pattern
WELCURE Shareholding History
WELCURE Shareholding History
Foreign Institutions
smallcases containing WELCURE stock
smallcases containing WELCURE stock
Looks like this stock is not in any smallcase yet.
WELCURE Events
WELCURE Events
WELCURE Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
WELCURE has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
WELCURE Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
WELCURE has not given any dividends in last 5 years
WELCURE Dividends
WELCURE Dividends
Hmm, looks like data is unavailable here. Please come back after some timeWELCURE Stock News & Opinions
WELCURE Stock News & Opinions
Articles & Videos
Earnings
Welcure Drugs & Pharmaceuticals reports standalone net profit of Rs 2.54 crore in the March 2025 quarter
Net profit of Welcure Drugs & Pharmaceuticals reported to Rs 2.54 crore in the quarter ended March 2025 as against net loss of Rs 0.02 crore during the previous quarter ended March 2024. Sales reported to Rs 21.21 crore in the quarter ended March 2025. There were no Sales reported during the previous quarter ended March 2024. For the full year,net profit reported to Rs 2.17 crore in the year ended March 2025 as against net loss of Rs 0.17 crore during the previous year ended March 2024. Sales reported to Rs 24.55 crore in the year ended March 2025. There were no Sales reported during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales21.210 0 24.550 0 OPM %3.020 -3.580 - PBDT2.550 0 2.79-0.13 LP PBT2.54-0.02 LP 2.78-0.17 LP NP2.54-0.02 LP 2.17-0.17 LP Powered by Capital Market - Live
3 weeks agoCapital Market - Live
Corporate
Welcure Drugs & Pharmaceuticals to conduct board meeting
Welcure Drugs & Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 29 May 2025.Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Welcure Drugs & Pharmaceuticals to discuss results
Welcure Drugs & Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 14 May 2025.Powered by Capital Market - Live
1 month agoCapital Market - Live
Earnings
Welcure Drugs & Pharmaceuticals reports standalone net profit of Rs 0.41 crore in the December 2024 quarter
Net profit of Welcure Drugs & Pharmaceuticals reported to Rs 0.41 crore in the quarter ended December 2024 as against net loss of Rs 0.03 crore during the previous quarter ended December 2023. Sales reported to Rs 8.84 crore in the quarter ended December 2024. There were no Sales reported during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales8.840 0 OPM %10.290 - PBDT0.91-0.02 LP PBT0.91-0.03 LP NP0.41-0.03 LP Powered by Capital Market - Live
4 months agoCapital Market - Live
Corporate
Welcure Drugs & Pharmaceuticals schedules board meeting
Welcure Drugs & Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 14 February 2025.Powered by Capital Market - Live
4 months agoCapital Market - Live
Earnings
Welcure Drugs & Pharmaceuticals reports standalone net profit of Rs 1.84 crore in the September 2024 quarter
Net profit of Welcure Drugs & Pharmaceuticals reported to Rs 1.84 crore in the quarter ended September 2024 as against net loss of Rs 0.10 crore during the previous quarter ended September 2023. Sales reported to Rs 24.55 crore in the quarter ended September 2024. There were no Sales reported during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales24.550 0 OPM %7.540 - PBDT1.85-0.09 LP PBT1.84-0.10 LP NP1.84-0.10 LP Powered by Capital Market - Live
7 months agoCapital Market - Live
Corporate
Welcure Drugs & Pharmaceuticals revises board meeting date
Welcure Drugs & Pharmaceuticals has revised the meeting of the Board of Directors which was scheduled to be held on 13 November 2024. The meeting will now be held on 14 November 2024.Powered by Capital Market - Live
7 months agoCapital Market - Live
Corporate
Welcure Drugs & Pharmaceuticals to hold board meeting
Welcure Drugs & Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 13 November 2024Powered by Capital Market - Live
7 months agoCapital Market - Live
Corporate
Welcure Drugs & Pharmaceuticals to hold board meeting
Welcure Drugs & Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 21 October 2024.Powered by Capital Market - Live
8 months agoCapital Market - Live
Corporate
Welcure Drugs & Pharmaceuticals to convene AGM
Welcure Drugs & Pharmaceuticals announced that the Annual General Meeting (AGM) of the company will be held on 30 September 2024.Powered by Capital Market - Live
9 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 2.38%, vs industry avg of 9.02%
Over the last 5 years, market share stayed at 0%